Literature DB >> 21843260

The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy?

Sameer H Patel1, David A Kooby, Charles A Staley, Juan M Sarmiento, Shishir K Maithel.   

Abstract

OBJECTIVE: Criteria for selecting patients to receive adjuvant chemotherapy in cases of resected intrahepatic or hilar cholangiocarcinoma (CC) are lacking. Some clinicians advocate the provision of adjuvant therapy in patients with lymph node (LN)-positive disease; however, nodal assessment is often inadequate. The aim of this study was to identify a surrogate criterion based on primary tumour characteristics.
METHODS: All patients who underwent resection for hilar or intrahepatic CC at a single institution between January 2000 and September 2009 were identified from a prospectively maintained database. Pathological factors were recorded. The primary outcome assessed was overall survival (OS).
RESULTS: In total, 69 patients underwent resection for hilar (n=34) or intrahepatic (n=35) CC. Their median age was 66 years and 27 patients (39%) were male. Median follow-up was 22 months and median OS was 17 months. Median tumour size was 5 cm. Overall, 23% of patients had a positive resection margin, 44% had perineural invasion, 32% had lymphovascular invasion (LVI) and 25% had positive LNs. The median number of LNs removed was two and the median number of positive LNs was zero. The presence of LVI was associated with reduced OS (11.9 months vs. 23.1 months; P=0.023). After accounting for all other adverse tumour factors, the presence of LVI persisted as the only negative prognostic factor for OS on multivariate Cox regression.
CONCLUSIONS: In patients who had undergone resection of hilar or intrahepatic CC, the presence of LVI was strongly associated with reduced OS. Thus the finding of LVI may potentially be used as a criterion in the selection of patients for adjuvant chemotherapy.
© 2011 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2011        PMID: 21843260      PMCID: PMC3183444          DOI: 10.1111/j.1477-2574.2011.00335.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  31 in total

1.  Surgical treatment of cholangiocarcinoma.

Authors:  F F Chou; S M Sheen-Chen; Y S Chen; M C Chen; C L Chen
Journal:  Hepatogastroenterology       Date:  1997 May-Jun

2.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

3.  A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables.

Authors:  T Okabayashi; J Yamamoto; T Kosuge; K Shimada; S Yamasaki; T Takayama; M Makuuchi
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

6.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.

Authors:  Tadahiro Takada; Hodaka Amano; Hideki Yasuda; Yuji Nimura; Takashi Matsushiro; Hiroyuki Kato; Takukazu Nagakawa; Toshimichi Nakayama
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

9.  Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroaki Nakamura; Akira Nakashima; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

10.  Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China.

Authors:  Liu Yubin; Fang Chihua; Jian Zhixiang; Ou Jinrui; Liu Zixian; Zheng Jianghua; Lin Ye; Jin Haosheng; Lu Chaomin
Journal:  Ann Surg Oncol       Date:  2008-06-11       Impact factor: 5.344

View more
  14 in total

1.  Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis.

Authors:  Sarah B Fisher; Sameer H Patel; David A Kooby; Sharon Weber; Mark Bloomston; Clifford Cho; Ioannis Hatzaras; Carl Schmidt; Emily Winslow; Charles A Staley; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2012-05-22       Impact factor: 3.647

2.  Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma.

Authors:  Megan E McNally; Amy Collins; Sylwia E Wojcik; James Liu; Jon C Henry; Jinmai Jiang; Thomas Schmittgen; Mark Bloomston
Journal:  HPB (Oxford)       Date:  2012-07-04       Impact factor: 3.647

3.  Synchronous Gall Bladder and Bile Duct Cancer: A Short Series of Seven Cases and a Brief Review of Literature.

Authors:  Harshal Rajekar
Journal:  J Clin Exp Hepatol       Date:  2016-11-21

4.  Prognostic Impact of Tumor Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: a Single-Center Experience of 659 Cases.

Authors:  Shin Hwang; Young-Joo Lee; Gi-Won Song; Kwang-Min Park; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-03-28       Impact factor: 3.452

5.  A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.

Authors:  Caroline E Poorman; Cecilia G Ethun; Lauren M Postlewait; Thuy B Tran; Jason D Prescott; Timothy M Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solórzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Charles A Staley; George A Poultsides; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2017-11-21       Impact factor: 5.344

6.  A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium.

Authors:  Cecilia G Ethun; Lauren M Postlewait; Nina Le; Timothy M Pawlik; Stefan Buettner; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Nipun Merchant; Kenneth Cardona; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2016-11-03       Impact factor: 5.344

7.  A new clinically based staging system for perihilar cholangiocarcinoma.

Authors:  Roongruedee Chaiteerakij; William S Harmsen; Carlos Romero Marrero; Mohammed M Aboelsoud; Albert Ndzengue; Joseph Kaiya; Terry M Therneau; William Sanchez; Gregory J Gores; Lewis R Roberts
Journal:  Am J Gastroenterol       Date:  2014-11-11       Impact factor: 10.864

8.  Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium.

Authors:  Lauren M Postlewait; Cecilia G Ethun; Nina Le; Timothy M Pawlik; Stefan Buettner; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Gerardo Vitiello; Kenneth Cardona; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2016-08-09       Impact factor: 3.647

9.  Prognostic factors in patients with middle and distal bile duct cancers.

Authors:  Hyung Jun Kwon; Sang Geol Kim; Jae Min Chun; Won Kee Lee; Yoon Jin Hwang
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

10.  The Prognostic Value of Lymphovascular Invasion in Truncal and Extremity Soft Tissue Sarcomas: An Analysis from the National Cancer Database.

Authors:  Cecilia G Ethun; Alexandra G Lopez-Aguiar; Jeffery M Switchenko; Theresa W Gillespie; Keith A Delman; Charles A Staley; Shishir K Maithel; Kenneth Cardona
Journal:  Ann Surg Oncol       Date:  2019-09-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.